IBRX
Health check
See the tests
- ✗Positive net income
- ✗Positive operating cash flow
- ✓Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by Coteau from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Live chart
What they do
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
For information only · Important disclosures
Grades vs sector
No sector grades for IBRX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.03 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.16 vs trailing $-0.97. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score -7.4 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $113.3M | $-351.4M | $-308.8M |
| 2024 | $14.7M | $-413.6M | $-398.1M |
| 2023 | $622.0K | $-583.2M | $-397.3M |
| 2022 | $240.0K | $-416.6M | $-415.7M |
| 2021 | $934.0K | $-346.8M | $-308.0M |
| 2020 | $605.0K | $-221.9M | $-173.4M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +678.6%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | -0.08 | -0.22 | -175.0% |
| 2026-05-07 | -0.07 | -0.08 | -20.0% |
| 2026-02-23 | -0.10 | -0.06 | +37.9% |
| 2025-11-04 | -0.10 | -0.07 | +30.0% |
| 2025-08-05 | -0.10 | -0.10 | – |
| 2025-05-12 | -0.14 | -0.15 | -7.1% |
| 2025-03-03 | -0.13 | -0.08 | +38.5% |
| 2024-11-12 | -0.18 | -0.12 | +33.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $51.2M | +93.9% |
| 2026-03-31 | $44.2M | – |
| 2025-12-31 | $38.3M | – |
| 2025-09-30 | $32.1M | – |
| 2025-06-30 | $26.4M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Stats refreshed 2026-10-22 22:21:21 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026